Tin tức & Cập nhật
Lọc theo Chuyên ngành:
AFP-L3, DCP predict HCC recurrence after liver transplant
Dual positivity for alpha-fetoprotein (AFP) bound to Lens culinaris agglutinin (AFP-L3) ≥15 percent and des-gamma-carboxyprothrombin (DCP) ≥7.5 can strongly predict majority of early hepatocellular carcinoma (HCC) recurrences following liver transplantation (LT), suggests a study.
AFP-L3, DCP predict HCC recurrence after liver transplant
13 Dec 2023
MAGNITUDE updates in Asian cohort boost NIRA-AAP benefit in BRCA+ mCRPC
In the second interim analysis of the Asian cohort from the phase III MAGNITUDE study, a combination regimen comprising niraparib and abiraterone acetate plus prednisone (NIRA-AAP) improved clinical outcomes in patients with BRCA+ metastatic castration-resistant prostate cancer (mCRPC).
MAGNITUDE updates in Asian cohort boost NIRA-AAP benefit in BRCA+ mCRPC
13 Dec 2023
Amivantamab-based regimens may alter EGFR-mutant NSCLC treatment paradigm in Asia
Updates from two MARIPOSA trials presented at ESMO Asia 2023 underpin the potential of amivantamab-based regimens for the treatment of locally advanced or metastatic EGFR-mutated non-small cell lung cancer (EGFRm NSCLC) in Asian subgroups.
Amivantamab-based regimens may alter EGFR-mutant NSCLC treatment paradigm in Asia
11 Dec 2023
Myeloma patients may benefit from mezigdomide-dexamethasone doublet
In a study evaluating heavily pretreated patients with relapsed and refractory multiple myeloma (R/R MM), the combination of mezigdomide and dexamethasone showed promising preliminary efficacy, with myelosuppression and infection as primary toxicities.
Myeloma patients may benefit from mezigdomide-dexamethasone doublet
08 Dec 2023
How does combination therapy fare as second-line treatment for NSCLC with EGFR mutation?
Combination therapy does not appear to have beneficial effects in terms of progression-free survival (PFS), overall response rate (ORR), disease control rate (DCR), and incidence of adverse events compared with monotherapy in patients with advanced nonsmall cell lung cancer (NSCLC) who failed first-line treatment with an epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor, a study has shown.